Protalix rises on European regulator's nod for genetic disorder drug

Protalix BioTherapeutics

05/05/2023 12:39

** U.S.-listed shares of Israeli drug developer Protalix
Biotherapeutics Inc  PBDA.F   PLX.N  rise 7.74% to $3.62
premarket 
    ** PLX says the European health regulator approved co and
partner Chiesi Global Rare Diseases' experimental therapy to
treat adult patients with Fabry disease 
    ** Fabry disease is a rare genetic disorder that could lead
to kidney  failure, heart failure, and stroke     
    ** Up to last close, the U.S.-listed shares of Protalix more
than doubled this year 

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))